Charles River Laboratories International (NYSE:CRL) reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earning
Lab services company Charles River Laboratories (NYSE:CRL) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales fell by 2.7% year...
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting results this Wednesday before the bell. Here’s what to look for. Charles River L...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...
Charles River Laboratories trades at $225.41 and has moved in lockstep with the market. Its shares have returned 11.4% over the last six months while the S&P...
Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Charles River Laborato...
Charles River Laboratories’ first quarter results reflected a mix of ongoing business transformation and operational adjustments. Management pointed to the i...
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi...
Charles River Laboratories International (NYSE:CRL) reported first-quarter 2026 results that management said were in line to slightly ahead of its prior outlook, while reaffirming its full-year organic revenue and non-GAAP earnings guidance and outlining a refreshed strategic framework under new Chi
Charles River Laboratories (NYSE: CRL) beat Q1 earnings estimates but lowered its FY2026 forecast. Analysts maintain positive outlook with raised price targets.
